In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead pays $11.2bn for HCV company Pharmasset

Executive Summary

In a bold move that gives it a stronger foothold in the competitive hepatitis C therapeutics market, Gilead Sciences Inc. paid $137 per share (a 96% premium), or $11.2bn, to acquire public antivirals biotech Pharmasset Inc. The purchase price is the highest ever paid for a clinical-stage biotech.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies